Because CaMKK2 deficiency licenses such an immunostimulatory TME landscape, we anticipate it will also synergize with other T-cell-dependent therapies, such as chimeric antigen receptor (CAR)-T cells and tumor vaccines. This evidence concerns the gene CAMKK2 and neoplasm.